Teva officials told the Journal that the company met with the FDA in October and raised questions about possible bias. It (TEVA) has said its application, which was filed two years before Momenta's, is stuck in bureaucratic limbo, and that it received delayed notice when the FDA changed the terms for evaluating the drugs.
This paragraph very much tells me that TEVA application for tL does not meet the FDA new standards.
Market Data 
Markets 
AI
